Recently, Sichuan Yuanda Shuyang Pharmaceutical, a wholly-owned subsidiary of Grand Life Science Group, has entered into an exclusive license agreement with Neoletix (Beijing), under which Sichuan Yuanda Shuyang Pharmaceutical will be granted an exclusive right to develop, register, and commercialize human recombinant factor VIII (project code: NX01) in the Greater China region.

Organized by the China International Exchange and Promotive Association for Medical and Health Care (CPAM) and the Renal Transplantation Branch of CPAM, and hosted by West China Hospital of Sichuan University, the 2022 Academic Annual Conference of Renal Transplantation Branch of CPAM and the 6th Huaxia Renal Transplantation Forum were held on July 15-17, 2022 in Chengdu City. There were more than 5,000 participants in this conference offline and online. Yuanda Shuyang Pharmaceutical participate